Trial Profile
Dose finding study to assess the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2019
Price :
$35
*
At a glance
- Drugs SK-PC-B70M (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors SK Chemicals
- 16 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 13 Nov 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.